Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8183655 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL1524081 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL1623752 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL452300 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL12431140 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL987381 | 1.00 | HDAC4 (0.63) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL11475389 | 0.86 | HDAC4 (0.50) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL2034678 | 0.84 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL8295172 | 0.84 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 | |
| SCHEMBL5217474 | 0.84 | FFAR1 (0.70) | HDAC4ALDH1A1SLC9A1HPGDFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 361 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | AURIMMED PHARMA, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2024-07-18 | — | — | US | disclosed |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3470407-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2024-01-24 | — | — | EP | disclosed |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | ALCON INC. (CH) | 2023-04-27 | — | — | US | disclosed |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | AURIMMED PHARMA, INC. | 2021-05-06 | — | — | US | disclosed |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2021-02-25 | — | — | US | disclosed |
| EP-3770148-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2021-01-27 | — | — | EP | disclosed |
| US-4269618-A | COMPRISING A THIOLCARBAMATE AND AN ANTIDOTE OF A HALOALKYLAMIDO COMPOUND; COATING CROP SEEDS; APPLYING TO THE SOIL | STAUFFER CHEMICAL COMPANY (US) | 1981-05-26 | — | — | US | disclosed |
| US-4267174-A | AND PROCESS FOR ADMINISTERING | BOEHRINGER MANNHEIM, GMBH (DE) | 1981-05-12 | — | — | US | disclosed |
| US-4254285-A | 1-Hydroxymethyl-1-1-oxo prostane derivatives of the E and F series | AMERICAN CYANAMID COMPANY (US) | 1981-03-03 | — | — | US | disclosed |
| US-4250325-A | ANTISECRETORY, BRONCHODILATOR, ANTIFERTILITY, AND ANTIINFLAMMATORY AGENTS; OXYTOCICS; MUSCLE STIMULANTS | AMERICAN CYANAMID COMPANY (US) | 1981-02-10 | — | — | US | disclosed |
| EP-0013107-A1 | 16-Hydroxy-16-vinyl (or cyclopropyl)-prostan-1-ols and pharmaceutical compositions containing the same | AMERICAN CYANAMID COMPANY (US) | 1980-07-09 | — | — | EP | disclosed |
| US-4160028-A | ANTIALLERGENS | CARLO ERBA S.P.A. (IT) | 1979-07-03 | — | — | US | disclosed |
| EP-0002590-A1 | Novel prostaglandin compounds, processes for the preparation thereof and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-06-27 | — | — | EP | disclosed |
| US-4137070-A | CONTAINING HERBICIDAL ANTIDOTE | STAUFFER CHEMICAL COMPANY (US) | 1979-01-30 | — | — | US | disclosed |
| US-4124376-A | HALOACETANILIDE HERBICIDE AND HALO-N,N-BISALKENYLAMIDE NONPHYTOTOXIC ANTIDOTE | STAUFFER CHEMICAL COMPANY (US) | 1978-11-07 | — | — | US | disclosed |
| US-4021224-A | THIOCARBAMATE, WEED PEST CONTROL, ANTIDOTES | STAUFFER CHEMICAL COMPANY (US) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486218-B2 | Compounds advantageous in the treatment of central nervous system diseases and disorders | SMN1; SMN2, HDAC6, CTSA | HDAC4 41/4885ALDH1A1 1386/4885SLC9A1 2475/4885 |
| US-20210130285-A1 | NOVEL COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, HDAC3 | HDAC4 18/4885ALDH1A1 1158/4885SLC9A1 2608/4885 |
| US-12018012-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | HDAC4 1635/4885ALDH1A1 2932/4885SLC9A1 4193/4885 |
| US-20210054007-A1 | RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | TACR1, TACR2, GPBAR1 | HDAC4 3062/4885ALDH1A1 1113/4885SLC9A1 1516/4885 |
| US-11312700-B2 | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | UACA, HRAS, MYLK | HDAC4 1635/4885ALDH1A1 2932/4885SLC9A1 4193/4885 |
| US-20230130470-A1 | ARYL CYCLOPROPYL-AMINO-ISOQUINOLINYL AMIDE COMPOUNDS | UACA, HRAS, MYLK | HDAC4 1635/4885ALDH1A1 2932/4885SLC9A1 4193/4885 |
| US-20240239739-A1 | COMPOUNDS ADVANTAGEOUS IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES AND DISORDERS | SMN1; SMN2, HDAC6, CTSA | HDAC4 41/4885ALDH1A1 1386/4885SLC9A1 2475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.